Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GB-4362

Monoclonal antibody · Antagonist of monomethyl auristatin E (MMAE) · developed by Generate Biomedicines

Phase 1 Most advanced trial
GENB Developer
1 Registered trials

What is GB-4362?

GB-4362 is a monoclonal antibody that binds and neutralizes unconjugated monomethyl auristatin E (MMAE), the cytotoxic payload released from some antibody-drug conjugates into the circulation. It does not bind MMAE within an intact antibody-drug conjugate. It is studied in urothelial cancer in combination with an MMAE-containing antibody-drug conjugate.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
monomethyl auristatin E (MMAE)
Mechanism
Antagonist of monomethyl auristatin E (MMAE)
Therapy area
Oncology
Developer
Generate Biomedicines (GENB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07484022 Phase 1 Advanced Urothelial Cancer Recruiting GENB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Urothelial CancerMetastatic Urothelial Carcinoma

More from Generate Biomedicines

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the GENB page.

Follow GENB, the company behind GB-4362

See GENB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GENB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.